Recent advances in medical management of benign prostatic hyperplasia: narrative review
Abstract
Benign prostatic hyperplasia (BPH) is a prevalent condition in aging men, commonly linked with lower urinary tract symptoms (LUTS) such as frequency, urgency, nocturia, and weak urinary stream, all of which significantly impact quality of life. Pharmacological therapy remains the first-line management, yet conventional agents like alpha-1 blockers and 5-alpha reductase inhibitors (5-ARIs) often face challenges due to poor adherence, sexual side effects, and suboptimal symptom control. Given the progressive nature of BPH and its increasing prevalence in the elderly worldwide, including India, there is a need for more effective and better-tolerated treatment options. A comprehensive literature review was performed using PubMed, Cochrane Library, Wiley Online Library, Google Scholar, and ClinicalTrials.gov. Studies published between 2020 and 2025 were included to capture recent therapeutic innovations. References from selected articles were also cross-examined to ensure completeness. Pharmacological advances: While α-blockers and 5-ARIs remain standard, they inadequately target BPH’s multifactorial pathophysiology involving inflammation, hormonal imbalance, and increased smooth muscle tone. Emerging therapies include phosphodiesterase-5 (PDE-5) inhibitors, which relax prostate and bladder smooth muscle, improving both LUTS and erectile function; β3-adrenoceptor agonists for bladder storage symptoms; and gonadotropin-releasing hormone antagonists that reduce prostate volume…
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.